15th Annual Drug Discovery Summit - New Hot Topics Announced

15th Annual Drug Discovery Summit 2014
2nd & 3rd June 2014, Geneva, Switzerland
http://www.drugdiscovery-summit1.com/

Oxford Global are pleased to announce the return of the Pharma R&D Europe Series, the leading pharmaceutical discussion forum in Europe.

The series is made up of the following events:
•15th Annual Drug Discovery Summit
•6th Annual Drug Development Congress
•2nd Annual Discovery Chemistry & Drug Design Congress

The first round of topics have now been confirmed for the 15th Annual Drug Discovery Summit, taking place on the 2nd & 3rd June 2014 in Geneva, Switzerland. Co-located with our 2nd Annual Discovery Chemistry congress, the 15th Annual Drug Discovery Summit topics include:

Diversity Screening at AstraZeneca: Lead Generation Through Internal Delivery and External Collaboration
•Development of the diversity screening strategy for 2014-2017
•Enabling a capability for phenotypic discovery
•Leveraging capability for Open Innovation

CONFIRMED SPEAKER:
Steve Rees, Vice President, Screening Sciences and Sample Management, AstraZeneca

Disease Modeling And Phenotypic Drug Screening For Diabetic Cardiomyopathy Using Human Induced Pluripotent Stem Cells
•Diabetic cardiomyopathy can be induced in vitro by environmental or genetic means
•The extent of patient-specific cardiomyopathy is clinically correlated
•Phenotypic screening identifies drugs that rescue the disease phenotype

Roberto Iacone, Group Head, Roche-Basel

3D and Phenotypic Screening: Where Do We Go In The Third Dimension?
•Relevance of cellular models for drug discovery
•Infrastructure for 3D and Phenotypic screening
•Outcome comparison for 2D and 3D screening

Adam Hill, Director, Head of Screening, Novartis

Our speaker programmes have been carefully researched, ensuring delegates are exposed to the highest level of expertise. Confirmed speakers so far include:
•Steve Rees, Vice President, Screening Sciences and Sample Management, AstraZeneca
•Robert Hayes, Vice President and Venture Leader, Centyrex Venture, Janssen
•Richard Sedrani, Executive Director, CPC / Expertise Platform Proteases / Medicinal Chemistry Unit, Novartis
•Ashwani Bahl, Senior Director Global External Research & Development, Eli Lilly
•Eckhard Ottow, Head Global External Innovation & Alliances Global Drug Discovery, Bayer HealthCare Pharmaceuticals
•Charlotte Deane, Director of the Systems Approaches to Biomedical Sciences Industrial DTC, Oxford University

To find out who else will be speaking at this two-day event, visit (http://www.drugdiscovery-summit1.com/speakers/)

Register your interest today to hear over 55 outstanding case studies and presentations, across 6 interactive streams:
•R&D Models For The Future
•Screening & Assays: Enabling Technologies
•Target Based Discovery
•Supporting Innovation: Data & Information Management
•Discovery Chemistry: Latest Case Studies
•Drug Design: Novel Approaches

Download the conference programme and view this two day event in more detail.
(http://www.drugdiscovery-summit1.com/download-agenda-marketing/)

Your booking will give you free access to the 6th Annual Drug Development Congress and the 2nd Annual Discovery Chemistry & Drug Design Congress

The Discovery Chemistry & Drug Design Congress proved a popular addition to the summit last year. This year the congress will include key case studies in chemical genetics, computational chemistry and flow chemistry. Presentations will also focus on early de-risking through drug design, focusing on the areas such as solubility, potency and selectivity.

Limited discounted places are available. Contact Danielle Dalby on +44(0) 1865 248455 or email mailto:d.dalby@oxfordglobal.co.uk for more information.